The Cigna Group (NYSE:CI) is back in focus after a strong Q4 2025 print, the closing of its Medicare Advantage divestiture to HCSC, and a landmark FTC settlement that reshapes the Express Scripts pharmacy benefit Business heading into 2026.

Key Highlights

  • The Cigna Group reported full-year 2025 adjusted Revenue of roughly $275 billion (up 11%) and adjusted EPS of $29.84 (up 9%), with Q4 2025 adjusted EPS of $8.08 beating consensus.
  • In March 2025, Cigna closed the sale of its Medicare Advantage, Medicare Part D, Medicare Supplement, and CareAllies businesses to HCSC for an Enterprise value of approximately $3.7 billion.
  • Express Scripts reached a "landmark" settlement with the FTC in February 2026 over insulin pricing allegations, agreeing to eliminate spread pricing and decouple rebates from list price.
  • Management raised the quarterly Dividend to $1.56 per share and repurchased roughly 11.9 million shares for about $3.6 billion in 2025, with more Buybacks built into the 2026 outlook.
  • 2026 guidance calls for at least $30.25 in adjusted EPS on roughly $280 billion in Revenue, even as Evernorth absorbs an estimated $500 million to $600 million headwind from PBM model changes.

 

The Cigna Group (NYSE:CI) has spent the last twelve months reshaping itself, and investors are now watching to see whether that work translates into a sustained re-rating. After the closing of its Medicare Advantage divestiture to Health Care Service Corporation (HCSC) in March 2025, a "low-drama" Q4 2025 Earnings beat in February 2026, and a long-awaited Federal Trade Commission settlement involving its Express Scripts pharmacy benefit unit, the stock is in focus because three of the largest overhangs of the past two years have either lifted or moved closer to resolution.

At the same time, Cigna has guided to a 2026 Earnings step-down inside its Evernorth Health Services segment as the company transitions toward a rebate-free pharmacy benefit model. That tension between near-term Margin compression and a cleaner long-term operating model is shaping the current debate around CI shares, and it is why both growth-oriented and risk-tolerant investors may be paying attention.

Company Overview

The Cigna Group is a global health services company organized around two principal segments. Cigna Healthcare provides medical, dental, behavioral, pharmacy, vision, supplemental health, and group disability and Life insurance, with a particular focus on the U.S. employer-sponsored commercial market and the international expat space. Evernorth Health Services houses the company's pharmacy benefit manager, Express Scripts, along with Accredo specialty pharmacy, eviCore utilization management, MDLIVE virtual care, and a growing suite of care delivery and benefit-management services.

After divesting its Medicare Advantage book, Cigna is now positioned primarily as a commercial health insurer plus a large, diversified health services platform. Evernorth has become the dominant contributor to Revenue and a large share of pretax adjusted Earnings, and the segment's growth profile, customer retention, and pharmacy-Margin trajectory now drive the bulk of the Investment narrative around CI.

The Cigna Group is headquartered in Bloomfield, Connecticut, trades under the ticker CI on the New York Stock Exchange, and is a constituent of the S&P 500.

Latest News Catalyst

Three catalysts have driven CI's recent trading.

First, on February 4, 2026, the FTC announced a settlement with Cigna's Express Scripts to resolve the agency's insulin-pricing lawsuit. The deal does not impose a fine, but Express Scripts agreed to eliminate spread pricing, decouple PBM compensation from list prices and rebates, relocate its Ascent group purchasing organization from Switzerland back to the United States, and submit to ten years of FTC monitoring. The FTC characterized the agreement as a structural overhaul that could save consumers up to $7 billion in out-of-pocket costs over a decade. The lawsuits against UnitedHealth's Optum Rx and CVS's Caremark remain active.

Second, the company reported Q4 2025 results on February 5, 2026, and described it as a "low-drama" quarter — meaning fewer surprises around stop-loss losses, fewer headlines around the FTC overhang, and a clear path to 2026 guidance.

Third, the closing of the Medicare divestiture to HCSC in March 2025 freed up about $3.7 billion of Capital and removed one of the most cost-pressured insurance books from Cigna's portfolio. The proceeds funded a sizable share repurchase program and helped support the Dividend increase announced alongside Q4 results.

Recent Earnings

For the fourth quarter of 2025, The Cigna Group reported total Revenue of roughly $72.5 billion, ahead of consensus estimates, and adjusted EPS of $8.08, also a beat. Evernorth Health Services contributed approximately $63.1 billion of fourth-quarter Revenue with about $2.2 billion of pretax adjusted Earnings, while Cigna Healthcare contributed about $11.2 billion of Revenue and roughly $734 million of pretax adjusted Earnings.

For the full year, Cigna delivered adjusted Revenue of about $275 billion (up roughly 11%) and adjusted EPS of $29.84 (up roughly 9%). The Cigna Healthcare medical care ratio (MCR) — the share of premiums spent on medical claims — tracked within management's full-year guidance range of 83.2% to 84.2%, even with elevated stop-loss claims that had pressured 2024 numbers. Quarterly readings included an MCR of 82.2% in Q1 2025 and 83.2% in Q2 2025, both reflecting deliberate repricing actions in stop-loss renewals.

Looking forward, management established 2026 guidance for consolidated adjusted Revenue of approximately $280 billion and adjusted EPS of at least $30.25, with one Wall Street outlet noting an updated April 30 commentary pointing to no less than $30.35. Evernorth's adjusted Operating Income is expected to step down in 2026 by roughly $500 million to $600 million as the segment transitions away from rebate-based PBM Economics, before what the company expects to be a 2027 recovery.

Stock Price Reaction and Market Sentiment

CI's market reaction to the Q4 print and the FTC settlement was constructive. Multiple Sell-Side notes flagged the quarter as a "meaningful catalyst" because it addressed several of the issues that had weighed on shares since 2024 — uncertainty over the FTC litigation, fears of additional Medicare losses, and concerns about stop-loss profitability. Shares delivered a roughly 7.5% return in the week following results, according to coverage at the time.

As of late April 2026, CI was trading near the high $280s with a market Capitalization of roughly $78 billion and a trailing P/E ratio in the low-teens range (around 12.8x by one widely cited metric). Investor sentiment is bifurcated: bulls point to the cleaner Business mix, the FTC overhang lifting, and aggressive Capital return; bears focus on the 2026 PBM Earnings reset, ongoing medical-cost Inflation, and persistent Regulatory Risk across the PBM industry. Analyst price targets compiled by various aggregators range broadly, generally clustering in a buy-leaning band, though investors may want to watch how consensus moves as 2026 quarterly results test the rebate-free transition.

Key Growth Drivers

Several drivers underpin Cigna's medium-term growth outlook.

Evernorth specialty pharmacy continues to scale through Accredo, which serves patients on complex therapies — an area with high Revenue per script and increasingly with biosimilar and oncology penetration. The company has highlighted biosimilar adoption (notably in immunology and oncology) as a tailwind for both Volume and reported margins.

GLP-1 drugs are a complicated but important driver. Evernorth's own research shows GLP-1s for weight management drove a meaningful share of total drug spend growth in 2024, with weight-loss GLP-1 utilization projected to climb materially again in 2025. While GLP-1s create cost pressure for insurers, for the Evernorth PBM, higher script volumes generally support Revenue and Earnings, particularly through programs like EncircleRx, which offers employers and plans a financial guarantee on GLP-1 trend.

Cigna's commercial health Business continues to grow through its select-segment focus on small and middle-market employers, a sticky stop-loss insurance offering for self-funded employers, and supplemental health products. Stop Loss, after a difficult 2024, is being repriced through 2025 and 2026 with the intent to restore margins.

Capital deployment is itself a driver of EPS growth. The company's 11.9 million share repurchase in 2025, combined with its updated 2026 buyback plan and Dividend hike to $1.56 per share quarterly, is expected to support per-share Earnings even as Evernorth absorbs the rebate-model transition.

Finally, international health and behavioral health expansion offer incremental, diversified growth that is less exposed to U.S. drug pricing politics.

Main Risks Investors Should Watch

Despite the more constructive setup, investors may want to watch several risk factors.

PBM regulation remains the largest single overhang. Even though Express Scripts has settled with the FTC, the broader political environment around drug pricing, rebate practices, and PBM transparency continues to evolve. Future state-level legislation, additional federal rulemaking, or follow-on private litigation could constrain margins.

Medical cost Inflation, particularly in stop-loss and specialty drug spend, has surprised the entire managed care industry over the last two years. If utilization trends continue to outrun pricing actions, the Cigna Healthcare MCR could move higher than guided, pressuring Earnings.

The 2026 Evernorth Earnings step-down — guided at $500 million to $600 million — depends on smooth client adoption of the new pharmacy Economics. A bumpier transition, or larger-than-expected client losses, would worsen the trajectory.

Concentration risk in pharmacy customer relationships is also relevant. Large clients have substantial Leverage in renewal negotiations, and any high-profile client loss could affect both Revenue and investor sentiment.

Finally, broader macro risks — Interest Rate moves affecting Investment income, FX exposure in international operations, and any acceleration of unfavorable healthcare policy out of Washington — round out the watch list.

Valuation Discussion

At roughly 12 to 13 times trailing Earnings and a price-to-sales ratio in the high 0.2x range, CI trades at a discount to many large-cap healthcare and managed care peers. That discount reflects the 2026 Evernorth headwind, lingering PBM regulatory questions, and the fact that the company's reported Revenue base is dominated by lower-Margin pharmacy distribution.

On a forward basis, using management's at-least $30.25 EPS guide for 2026, the stock trades at single-digit to low-double-digit forward Earnings multiples depending on share price. For investors comfortable with the 2026 reset thesis — and the company's stated expectation of a 2027 recovery — the current valuation could screen as reasonable. For those skeptical of the structural PBM environment or worried about further medical cost surprises, the discount may be deserved. As always, valuation alone is not a buy or sell signal, and individual investors should consider their own Risk tolerance and time horizon.

Bull Case

Bulls argue that The Cigna Group stock is set up for a multi-year re-rating. The Medicare divestiture removed a structurally pressured Business and generated proceeds for Buybacks. The FTC settlement removes a major overhang and forces a transparent PBM model that, while temporarily Margin-dilutive, may ultimately make Express Scripts more defensible against future regulation.

Bulls also point to the Long-term Growth runway in specialty pharmacy, behavioral health, and GLP-1-related programs, plus a track record of disciplined Capital return. With shares trading at a low-teens P/E and a growing Dividend, the bull case sees a setup where modest multiple expansion combines with EPS growth and Buybacks to deliver attractive total returns.

Bear Case

Bears counter that 2026 is structurally a down year for Evernorth, that PBM regulation is far from done, and that medical cost trends across the U.S. system remain unpredictable. They worry that the rebate-free model could prove harder to monetize than management projects, that GLP-1 spend creates large risk-pool issues for plan sponsors, and that the loss of the Medicare Business reduces Diversification.

In the bear view, the current valuation is not a free lunch — it reflects real, ongoing risk. A weaker 2026 print, an unfavorable medical-cost trend, or a renewed political push against PBMs could all keep the stock range-bound or worse.

Investor Takeaways

  • Q4 2025 results and 2026 guidance suggest the major near-term overhangs around CI have moved closer to resolution, but a clear Earnings reset still sits inside Evernorth.
  • Capital return remains a meaningful piece of the thesis, with a higher Dividend, large Buybacks, and proceeds from the HCSC divestiture supporting EPS.
  • Risk-tolerant investors may be paying attention to whether the rebate-free PBM transition can be executed with limited client attrition.
  • The valuation looks reasonable on most traditional metrics, but the discount to peers reflects genuine PBM and medical-cost risk that has not gone away.

Conclusion

The Cigna Group stock enters the rest of 2026 with a clearer narrative than it has had in years. The Medicare divestiture is closed, the FTC settlement is signed, the Q4 2025 print landed cleanly, and management has put forward an at-least $30.25 EPS guide for 2026 alongside an enlarged Dividend and continued Buybacks. At the same time, the rebate-free transition inside Evernorth introduces a real, quantified Earnings headwind that investors will need to monitor through quarterly results.

For investors weighing CI today, the setup is one of resolution and reset — major overhangs lifting, but a one-year Earnings air-pocket to digest. The Cigna Group stock is therefore most likely to interest investors who can look across the 2026 transition toward a normalized 2027 Earnings base, who value the company's combination of commercial Health Insurance and specialty pharmacy, and who are comfortable with the regulatory complexity that comes with owning a large U.S. PBM. As always, this article is for informational purposes only and is not financial advice; investors should do their own research and consider their own circumstances before making any Investment decision.